Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Microba Life Sciences Limited ( (AU:MAP) ).
Microba Life Sciences Limited has received a $3 million R&D Tax Incentive refund from the Australian Government for its research and development activities in the 2024/2025 financial year. This financial boost strengthens Microba’s cash position and supports its ongoing innovation in gastrointestinal diagnostics and therapeutics, which are pivotal in delivering transformative health outcomes globally.
The most recent analyst rating on (AU:MAP) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences Limited is a leader in microbiome health and human care, offering clinical-grade microbiome tests aimed at improving health outcomes. The company focuses on delivering transformative health solutions through advanced gastrointestinal diagnostics and a clinical-stage therapeutics pipeline.
Average Trading Volume: 622,557
Technical Sentiment Signal: Sell
Current Market Cap: A$45.06M
For an in-depth examination of MAP stock, go to TipRanks’ Overview page.